ArticleScientific reports2026
Advanced glycation end products and the CALLY index reflect inflammatory burden in familial Mediterranean fever.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean Fever (FMF) is a prototypical autoinflammatory disease characterized by recurrent inflammatory attacks and persistent subclinical inflammation. Advanced glycation end products (AGEs) accumulate under conditions of chronic inflammation and oxidative stress and are linked to metabolic and cardiovascular complications. The C-reactive protein-albumin-lymphocyte (CALLY) index has been proposed as a composite biomarker reflecting inflammatory and nutritional status. However, the relationship between tissue AGE accumulation and the CALLY index in FMF remains unclear. This study aimed to evaluate tissue AGE accumulation using skin autofluorescence (AGE-SAF) in patients with FMF and to investigate its associations with the CALLY index, inflammatory markers, metabolic parameters, and clinical characteristics. This cross-sectional study included 87 FMF patients and 52 healthy controls. AGE-SAF was measured non-invasively using an AGE Reader™ device. Clinical and laboratory data were collected, and the CALLY index was calculated from C-reactive protein (CRP), albumin, and lymphocyte count. Non-parametric tests and Spearman's correlation analyses were applied. AGE-SAF levels were significantly higher in FMF patients than controls (2.06 ± 0.44 vs. 1.70 ± 0.20 AU; p < 0.001). AGE-SAF was elevated in FMF and correlated with inflammatory and metabolic markers, while showing an inverse association with the CALLY index.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.